twitter   linkedin

KMT Hepatech, Inc. provides efficient and cost-effective in vivo research services utilizing our proprietary platform technology of small animal model, the KMT MouseTM.

The KMT MouseTM is a chimeric mouse model with humanized liver with stable human hepatocytes engraftment of up to 95 per cent.

We are proud to acknowledge that generated in KMT MouseTM drug therapy responses parallel those seen in humans during clinical trials.

Due to the expanding interest in the humanized liver mouse model across a wide range of drug development fields, the company now offers services in the following areas:

  • Infectious diseases, such as Hepatitis C, Hepatitis B and Malaria
  • Safety toxicity: early assessment of potential hepatotoxicity in in vivo settings prior to first-in-human studies
  • Characterization of human-type drug and lipoprotein metabolism in in vivo settings prior to first-in-human studies

KMT Hepatech, Inc. owns an international patent portfolio that includes coverage of the uPA chimeric mouse model of HCV infection and on the uPA chimeric mouse for all potential applications including HBV, malaria and studies of toxicity, drug and lipoprotein metabolism.

The KMT MouseTM is your essential tool for therapeutics and vaccine development.

News and Events

  1. EASL Liver Meeting image small

    The International Liver Congress 2016

    April 06 2016

    Connect with KMT Hepatech representative at EASL meeting in Barcelona

  2. BIO-Europe Spring 2016 image

    BIO-Europe Spring 2016

    April 03 2016

    VP of Operations Mr. Kaz Fortuna attending BIO-Europe Spring conference in Stockholm early April

  3. KMT Mouse folder

    15th Anniversary of uPA-SCID mouse model with highly humanized liver

    February 29 2016

    15 years of in vivo services with proprietary KMT Mouse - uPA/SCID mouse model with stable human hepatocyte engraftment

  4. »more